Predictors of response to percutaneous ethanol sclerotherapy (PES) in patients with venous malformations: Analysis of patient self-assessment and imaging  by Yun, Woo-Sung et al.
From the American Venous Forum
Predictors of response to percutaneous ethanol
sclerotherapy (PES) in patients with venous
malformations: Analysis of patient self-assessment
and imaging
Woo-Sung Yun, MD,a Young-Wook Kim, MD,a Kyung-Bok Lee, MD,a Dong-Ik Kim, MD,a
Kwang-Bo Park, MD,a Keon-Ha Kim, MD,a Young-Soo Do, MD,a and Byung-Boong Lee, MD,b
Seoul, Korea; and Washington, DC
Background: Percutaneous ethanol sclerotherapy (PES) is the primary tool in the treatment of venous malformations
(VM). However, PES has known serious complications. This study is aimed at identifying predictors of good response to
PES in patients with VM to improve patient selection.
Methods: We performed a retrospective, cross-sectional study of 158 VM patients (mean age, 14.3 years, male 42%) who
underwent ethanol sclerotherapy at a specialized vascular malformation center. For clinical result assessment, patients or
parents in pediatric patients answered questions on symptomatic, functional, and cosmetic improvement after PES. In
each category, the possible choices were markedly improved, moderately improved, no change, moderately worse, or
markedly worse compared with pretreatment status. A “good response” was defined as one or more areas of marked
improvement on the self-assessment in conjunction with marked improvement on post-treatment images (>30% decrease
in maximal diameter of VM on magnetic resonance imaging [MRI] or >50% decrease in abnormal blood pool ratio on
whole body blood pool scintigraphy [WBBPS] compared with pretreatment images). To determine predictors of a good
response to PES, uni- and multivariate analysis were conducted on demographics (age, gender), clinical features of VM
(location, size, depth of involved tissue, presence of associated lymphatic malformation, MRI findings; well-defined vs
ill-defined margin, characteristics of venous drainage during PES) and treatment variables (number of PES sessions,
maximal concentration and dosage of ethanol used in PES, adjuvant therapy).
Results: Symptomatic, functional, and cosmetic improvement was 28%, 27%, and 34%, respectively, based on patient
questionnaires. Based on imaging studies, 42 patients (27%) had markedly improvement. Composite outcome combining
questionnaire results and imaging study showed that 16% of patients had a “good response”. On multivariate analysis,
female gender (odds ratio [OR]: 4.49, 95% confidence interval [CI]: 1.24-16.28), no or delayed visualization of drainage
vein (OR: 9.22, 95% CI: 1.79-47.51), and a well-defined margin on MRI (OR: 13.38, 95% CI: 2.84-63.12) were
independent predictors of “good response” to PES.
Conclusions: PES should be performed in selected patients in order to obtain the best outcomes and minimize
complications. No or delayed visualization of drainage vein on initial direct puncture venogram, a well-defined margin on
MRI, and female gender were statistically significant predictors of a “good response” to PES and may be useful in
selecting patients. ( J Vasc Surg 2009;50:581-9.)Venous malformations (VM) are the most common
type of vascular malformation and account for 44% to 64%
of all vascular malformation.1,2 The clinical presentation of
venous malformations (VM) vary in symptom, site, depth
of involvement, and can be combined with other type of
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(LM) and capillary malformation (CM). For treatment of
VM, sclerotherapy, embolization, and surgical excision
have been reported.3 Sclerotherapy has become the main-
stay of treatment while surgical excision alone has a limited
role in most patients due to the potential for functional and
cosmetic problems.1,4-6 With sclerotherapy, several agents
are available. Of these, ethanol is the most common agent
and its efficacy and potential complications are relatively
well described.7-9
It is apparent that some VM lesion responds well to
sclerotherapy while others do not. Reported outcomes of
percutaneous ethanol sclerotherapy (PES) vary and are
dependent on proper patient selection. Previous authors
often used absolute VM size reduction or patient self-
assessment to document success of VM treatment.10-12
There have been reports describing the use of magnetic
resonance imaging (MRI) or phlebographic findings to
assess treatment success.11,13 Only a few reports10 perform
581
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rotherapy response. Such predictors would be important in
helping to select the proper patients and minimize the side
effects of unfruitful PES. This article attempts to determine
predictors of good response to PES in patients with VM.
METHODS
Patients. We retrospectively reviewed a patient data-
base in a specialized vascular malformation clinic from the
period January 1995 to June 2008. Before conducting this
study, Institutional Review Board approval was obtained.
Venous malformation (VM) was diagnosed based on
clinical findings and imaging studies such as MRI, whole
body blood pool scintigraphy (WBBPS) using Tc-99m red
blood cells (Biad, Trionix Research Laboratory, Twinsburg,
Ohio), and/or duplex ultrasonography. In addition to pure
VM, predominantly venous defects, which were combined
with LM or CM, were also included. Patients with an arterio-
venous fistula component, whether gross or micro, were ex-
cluded from the study. Figure 1 demonstrates our treatment
of VM patients. Among 1045 patients diagnosed with VM,
158 patients with data of treatment outcome assessment avail-
able were included in this study.
Preprocedural considerations. In selecting candi-
dates for PES, patients’ age (pediatric or adult), body
weight (BW), clinical symptoms and signs, location of VM
(proximity to airway, eye, ear, joint), depth from skin
(subcutaneous vs deep), and coexisting deep venous anom-
alies were considered. The indication for PES have previ-
ously been described elsewhere.1 Our indications for PES
in patients with VM were various according to its location
of VM lesion. Patients often came to the hospital on a
cosmetic reason when lesions involve the head and neck.
Patients with VM involving the extremity or trunk sought
medical care with symptom of pain or severe discomfort
due to acute phlebitis, joint involvement, or chronic venous
hypertension. Sometimes patients were treated for the
Fig 1. Treatment of patientsbloody or serous discharge from the cutaneous lesion.In patients with head and neck VM, an MRI was
thoroughly reviewed to avoid airway obstruction or cranial
nerve palsy after PES. For those patients with head and neck
VM close to the upper airway, endotracheal intubation was
maintained after PES treatment until the risk of airway
obstruction safely diminished. Patients with VM at the
angle of the mandible underwent facial nerve branch map-
ping on the skin using electric stimulation in order to avoid
needle injury or direct ethanol injection into the facial nerve
branches during PES. In patients older than 15 years of age,
with large VM requiring large amount of ethanol (0.5
mL/Kg of BW) or those with cardiopulmonary depression
during previous PES, a pulmonary artery catheter was
utilized to monitor pulmonary artery pressure (PAP).
Procedural details of PES. All PES was performed
under general anesthesia and fluoroscopy. A 21 gauge
needle was used to percutaneously access the VM lesion. A
measurement of 5 mL of contrast (iobitridol, Xenet 300;
Guerbet, Cedex, France) was injected to observe the char-
acteristics of the drainage vein. Some VM lesions showed
immediate drainage of contrast while others had no or
delayed drainage after the initial contrast injection (Fig 2).
When drainage vein was immediately visualized, drainage
vein compression was attempted manually or with a pneu-
matic cuff to increase exposure time of the sclerosing agent
in the VM lesion. When manual compression was per-
formed, direct compression over the drainage vein was
attempted under fluoroscopy. When the pneumatic cuff
compression was applied on the purpose of drainage vein
blockage, a tourniquet was inflated to a pressure of 50 to 60
mmHg. A proximal tourniquet was not routinely used due
to the concern for pulmonary vasospasm or pulmonary
embolism due to a sudden influx of ethanol into the pul-
monary circulation upon sudden deflation of tourniquet.
The sclerosing agent was 60% to 100% ethanol (upper
limit of 100% ethanol 1 mL/Kg of BW/session). Pure
ethanol was routinely used, except in cases where the lesion
venous malformations (VM).involved skin or located near a nerve or major vascular
ein. C
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prevent skin necrosis, nerve damage, or deep vein throm-
bosis. Five to 10 minutes after ethanol injection, a
venogram was performed to check for residual filling of the
VM lesion. If present, a repeat session of PES was per-
formed at least 6 weeks later to allow for healing and
function of the local tissue.
After PES, patients who received large doses of ethanol
(0.5mL/Kg of BW) were monitored in the ICU until PAP
and other vital signs returned to pretreatment levels. For
patients with VM located near the airway, tracheal intubation
was our routine, and flexible laryngoscopy was used to assess
the degree of edemaprior to extubation. For patientswhohad
severe swelling or tenderness, anti-inflammatory agents, ste-
roids, and ice packs were used. In limbs lesions, a venous
duplex scan was routinely performed the day after treatment
to rule out deep venous thrombosis.
We made a protocol to check WBBPS on yearly basis
for all patients whether the patients were treated or not in
order to assess volume changes of VM lesion. MRI was
followed when more detailed anatomic information was
required before or after PES to establish a plan for the
subsequent treatment.
PES outcome assessment. To assess treatment out-
comes of VM, we used postprocedure imaging (MRI
and/or WBBPS) and patient self-assessment question-
naires that evaluated three areas: symptomatic, functional,
and cosmetic outcomes (Appendix, online only). In each
category, possible answer choices were markedly worse,
moderately worse, no change, moderately improved, and
markedly improved. In pediatric patients, parents were
asked to complete the questionnaire.
Pre- and post-treatment image MRI and/or WBBPS
were compared. Maximal VM diameter was measured with
electronic calipers, and lesion-to-whole body blood pool
count ratio was measured by a semiquantitative method on
WBBPS. Marked improvement by imaging was defined as
30% decrease in maximal MRI diameter of VM or 50%
decrease in abnormal blood pool ratio on WBBPS com-
Fig 2. Characteristics of venous drainage from venous
PES. A and B, No or delayed visualization of drainage vpared to pretreatment images (Fig 3).A “good response” to PES was then defined as at least
one area of marked improvement on the clinical assessment
(symptomatic, cosmetic, or functional) and marked im-
provement on post-treatment images. Patients who did not
have a “good response” were considered to have a “no-
good response”.
Statistical analyses. To determine predictors of good
response to PES, uni- and multivariate analyses were con-
ducted on demographic (age, gender) and clinical variables
(location, size of VM, depth of tissue involve, presence of
associated LM or CM, MRI findings, well-defined vs ill-
defined margin, and characteristics of venous drainage dur-
ing PES) and treatment variables (number of PES sessions,
maximal concentration and total dosage of ethanol in-
jected, and adjuvant therapy).
For univariate analysis, 2 test and Mann-Whitney test
were used to compare variables between “good response”
group and “no-good response” group. Multivariate analy-
sis was performed with binary logistic regression model.
P values  .05 were considered to be statistically sig-
nificant. Statistical analysis was performed with the SPSS
software (SPSS version 12.0.1; SPSS Inc, Chicago, Ill).
RESULTS
Patient demographic and clinical data is shown in Table I.
A total of 654 PES sessions were performed in 158 patients
with VM (median, 3.0 sessions/patient). Eighty percent of
patients (127/158) required more than one PES session.
The details of PES are shown in Table II. Regarding
adjuvant treatment, 13 patients underwent local excision
and five patients underwent surgical resection of a lateral
embryonal vein after PES. In superficial VM lesions, there
were 11 ethanolamine oleate sclerotherapy and 14 foam
sclerotherapy with sodium tetradecil sulfate following PES.
Table III shows PES complications. There were a total
of 20 patients with nerve palsies. By location, the most
common site of nerve palsy was in the upper extremity. Five
nerve palsies occurred in the 14 upper extremity VMs for a
36% palsy rate in the upper extremity, a significantly greater
rmations (VM) on a direct puncture venogram during
and D, Immediate visualization of drainage vein.malforate compared with head and neck, lower extremity or
e ne
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VMs, 9% (6/9); lower extremity VMs, 14% (8/59); trunk
VMs, 5% (1/19). There were three incidences of perma-
nent peroneal nerve palsy and 17 incidences of temporary
palsy with a mean recovery time of 5.4 months (range 1 to
24months). An 11-year-old female patient with a 5 cmVM
lesion of the back in close proximity to the sixth to eighth
thoracic spine (Fig 4) had a complication of transient spinal
cord ischemia following PES with 13 mL of 100% ethanol.
Twelve hours following PES injection, the patient devel-
oped bilateral lower extremity weakness, urinary inconti-
Fig 3. Imaging studies showing “good response” to p
post-PESMRIs showing diminished size of venous malfo
WBBPSs showing diminished abnormal blood pool in thnence, and paresthesia of the left medial foot. MRI showedhigh signal intensity and discontinuous enhancement in
spinal cord at the level of T6 to T12 consistent with acute
or subacute spinal cord ischemia. She was placed on ste-
roids and symptoms resolved in 7 days.
Patient self-assessment questionnaire results are given
in Table IV. Patients reported “marked improvement” in
symptoms 28% (26/94), function 27% (19/71), and cos-
mesis 34% (53/158). “Marked improvement” was noted in
at least one category in 41% (65/158) (Table IV).
Post-treatment WBBPSs were available in 132 (84%)
patients and 20% of patients showed “marked improve-
neous ethanol sclerotherapy (PES). A and B, Pre- and
ions (VM) lesion after PES. C and D, Pre- and post-PES
ck after PES.ercuta
rmatment”. Follow-up MRIs were available in 123 (78%) pa-
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In total, 42 (27%) of 158 patients revealed “marked im-
provement” on follow-up imaging study. Combining ques-
tionnaire and imaging results, a “good response” was
achieved in 16% (25/158) of patients after PES.
Table V demonstrates results of univariate analysis for
“good response” to PES. Female gender, non-extremity
VM, small size (5 cm in diameter), poor drainage from
VM during PES, and well-defined margins on MRI were
significantly associated with a good response to PES.
On multivariate analysis, female gender (odds ratio
[OR]: 4.49, 95% confidence interval [CI]: 1.24-16.28), no
or delayed visualization of drainage vein (OR: 9.22, 95%
CI: 1.79-41.51), and a well-defined margin on MRI (OR:
13.38, 95% CI: 2.84-63.12) were independent predictors
of good response to PES (Table VI).
DISCUSSION
Clinical features of VM ranges from asymptomatic var-
Table I. Demographic and clinical data of VM patients
N  158 patients
Age at first PES, mean (range) 14.3  11.5 (1-58) years
Gender, male 67 (42%)
Type of VM
Pure VM 122 (77%)
VM combined with LM 16 (10%)
VM combined with CM 17 (11%)
VM combined with LM and CM 3 (2%)
Location of VM treated
Head and neck 66 (42%)
Trunk 19 (12%)
Extremity 73 (46%)
Upper extremity 14 (9%)
Lower extremity 59 (37%)
Clinical presentation
Swelling or mass 93 (59%)
Episode of pain or tenderness 94 (60%)
Varicosity 75 (48%)
Lateral embryonal vein 9 (6%)
Skin discharge 3 (2%)
Limb length discrepancy (2 cm) 4 (3%)
Size of VM on MRI:
Maximal diameter 5 cm 48 (30%)
Maximal diameter 5 cm 110 (70%)
Tissue involvement of VM
Only skin or subcutaneous tissue 29 (18%)
To the skeletal muscle 105 (66%)
To the bone or joint 24 (15%)
MRI finding
Well-defined margin 29 (18%)
Poorly-defined margin 129 (82%)
Visualization of drainage vein on a
direct puncture venogram
No or delayed 14 (9%)
Immediate 144 (91%)
PES, Percutaneous ethanol sclerotherapy; VM, venous malformations; LM,
lymphatic malformation; CM, capillary malformation; MRI, magnetic reso-
nance imaging.icosities or vascular lesions to symptomatic lesions causingepisodic pain or swelling from thrombophlebitis, bleeding,
or even significant body disfigurement. The severity of the
clinical features is related to the location and extension of
lesion, and coexistence of other type vascular malforma-
tion (capillary malformation or lymphatic malformation)
and/or tissue hypertrophy. Head and neck VM usually
cause cosmetic problems, airway obstruction, oral bleed-
ing, or tongue motion abnormalities. Extremity or trunk
VMs usually present with pain due to thrombophlebitis,
limb swelling and heaviness, bleeding, or limb length or
Table II. Details of percutaneous ethanol sclerotherapy
(PES) for VM patients
Details No (%)
Number of PES/patient, mean 4.1 (1-22)
5 sessions 123 (78)
6-10 sessions 25 (16)
10 sessions 10 (6)
Maximal concentration of ethanol used
 80% 5 (3)
80%-99% 19 (12)
100% 134 (85)
Amount of ethanol used/session, mL of 100%
ethanol/Kg of BW, median/IQR 0.3/0.3
Adjuvant treatment with PES
Local excision of VM 13 (8)
Surgical resection of lateral embryonal vein 5 (3)
Use of ethanolamine oleate for skin VM lesion 11 (7)
Foam sclerotherapy with sodium tetradecil sulfate 14 (9)
PES, Percutaneous ethanol sclerotherapy; VM, venous malformations; BW,
body weight; IQR, interquartile range.
Table III. Complications of percutaneous ethanol
sclerotherapy (PES)
Complications No (%)
Local complications
Skin necrosis 12 (8)
Deep vein thrombosis 0
Nerve palsy 20 (13)
Head and neck nerve 6 (4)
Sensory 4
Motor and sensory nerve 2
Lower extremity nerve 8 (5)
Motor nerve 1
Sensory nerve 2
Motor and sensory nerve 5
Upper extremity or finger nerve 5 (3)
Motor nerve 0
Sensory nerve 2
Motor and sensory nerve 3
Spinal cord 1 (1)
Systemic complications
Transient pulmonary hypertensiona 2 (1)
Elevated liver enzyme 3 (2)
Cardiac arrhythmia 1 (1)
Hemoglobinuria 12 (8)
aTransient pulmonary hypertension was defined as mean pulmonary artery
pressure (PAP)  25 mm Hg.size discrepancy.
imaging.
percutaneous ethanol sclerotherapy (PES) in a patient who de
JOURNAL OF VASCULAR SURGERY
September 2009586 Yun et alThe complex morphologic and hemodynamic charac-
teristics of VM make patient selection difficult. Sclerother-
apy, the mainstay of treatment, is aimed at eradicating or
reducing abnormal blood vessels by endothelial damage,
inflammation, thrombosis, fibrosis, and resultant oblitera-
tion of the VM lesion. Various sclerosing agents have been
used including ethanol, ethibloc (radiopaque chemical scle-
rosant based on ethanol, corn protein, oleum papaveris,
and propylene glycol), sodium tetradecil sulphate, polydo-
canol, ethanolamine oleate, and bleomycin.7-9,14-19
Among these, pure ethanol is the most powerful scle-
rosant. The basic mechanism of pure ethanol is cellular
dehydration and vascular wall protein denaturation.7 Use
of ethanol is limited due to its local (pain, cellulitis, com-
partment syndrome, perivascular or local tissue damage
such as skin necrosis, nerve injury, and deep venous throm-
bosis) and systemic (central nervous system depression,
hypoglycemia, hypertension, distal embolization, remote
organ damage, pulmonary vasospasm, and blood cell dam-
age) side effects.7,10,20,21 In our series, 27% of patients who
underwent PES had one or more complications. There was
one mortality after PES secondary to cardiovascular col-
lapse. This patient case was not included in this series owing
to a lack of follow-up imaging.
Considering the potential for local and systemic toxic-
ity of ethanol, proper patient selection for PES is critical to
achieve the best results and minimize complications. There
is no standardized metric to assess treatment outcome after
sclerotherapy for VM. Some authors have relied on ques-
tionnaire based on patient assessment 11 while others have
compared pre- and post-treatment photography.10,15
Comparison of radiographic imaging studies have rarely
been used to assess treatment.
In our clinical practice, we have observed clinical im-
, (B), and (C) and direct puncture venogram (D) during
veloped transient spinal cord ischemic symptom.Table IV. Outcomes of PES
Clinical outcomes assessed
by questionnaire Frequency (%)
Symptomatic improvement (n  94)
Markedly worse 2 (2)
Moderately worse 3 (3)
No change 44 (47)
Moderately improved 19 (20)
Markedly improved 26 (28)
Cosmetic improvement (n  158)
Markedly worse 2 (1)
Moderately worse 3 (2)
No change 47 (30)
Moderately improved 53 (34)
Markedly improved 53 (34)
Functional improvement (n  71)
Markedly worse 2 (3)
Moderately worse 5 (7)
No change 25 (35)
Moderately improved 20 (28)
Markedly improved 19 (27)
Post-treatment image compared with
pretreatment image
Lesion-to-whole body blood pool count
ratio with semi-quantitative
method on WBBPS (n  132)
Increase 10% 19 (14)
No or minor (10%) change 31 (23)
Diminished 10% and 50% 55 (42)
Diminished 50% 27 (20)
Maximal diameter of VM on MRI
(n  123)
Increased 10% 22 (18)
No or minor (10%) change 57 (46)
Decreased 10% and 30% 18 (15)
Decreased 30% 26 (21)
PES, Percutaneous ethanol sclerotherapy; VM, venous malformations;
WBBPS, whole body blood pool scintigraphy; MRI, magnetic resonanceFig 4. Pretreatment magnetic resonance imaging (MRI) (A)provement after sclerotherapy for VM despite a lack of
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noted the converse. There have been marked reduction of
VMmass on imaging without improvement clinically. This
discrepancy between clinical and morphologic response
Table V. Univariate analysis of variables to predict
“good response” to PES for VM patients
Variables
Response to PES
P
Good
(n  25, 16%)
No-good
(n  133, 84%)
Age .554a
20 years 20 (80) 99 (74)
20 years 5 (20) 34 (26)
Gender .042a
Male 6 (24) 61 (46)
Female 19 (76) 72 (54)
Type of VM .875a
Pure VM 19 (76) 103 (77)
Combined with LM or
CM 6 (24) 30 (23)
Location of VM .001a
Non-extremity 21 (84) 64 (48)
Extremities 4 (16) 69 (52)
Size of VM .037a
5 cm 12 (48) 36 (27)
5 cm 13 (52) 97 (73)
Visualization of drainage
vein .002b
No or delayed 7 (28) 7 (5)
Immediate 18 (72) 126 (95)
VM margin on MRI .001a
Well-defined 13 (52) 16 (12)
Poorly-defined 12 (48) 117 (88)
Involved tissue 1.000b
Skin or subcutaneous
tissue only 4 (16) 25 (19)
Muscle, bone, or joint 21 (84) 108 (81)
Total session number of
PES .515b
1-5 sessions 21 (84) 102 (77)
6-10 sessions 4 (16) 21 (16)
11 or more sessions 0 10 (7)
Maximal concentration
of ethanol used
during PES .892b
80% 1 (4) 4 (3)
80%-99% 3 (12) 16 (12)
100% 21 (84) 113 (85)
Amount of ethanol
used/session,
median/IQR .904c
mL of 100% ethanol/
Kg of BW 0.3/0.4 0.3/0.3
Adjuvant treatment with
PES .142a
Yes 3 (12) 34 (26)
No 22 (88) 99 (74)
PES, Percutaneous ethanol sclerotherapy; VM, venous malformations; LM,
lymphatic malformation; CM, capillary malformation; BW, body weight;
IQR, interquartile range; MRI, magnetic resonance imaging.
a2 test.
bFisher exact test.
cMann-Whitey test.make assessment of VM treatment difficult.12 Therefore,we used both clinical and radiologic criteria to assess re-
sponse to PES. Clinical response assessment is based on the
patient self-assessment and not on the health care provider
assessment. In our series, a “good response” was obtained
only in 16% of patients, lower than in other reported series.
Our definition of a “good response” is stricter than other
reports.
To define good response to PES, we used strict criteria
to obtain more powerful evidence on a statistical analysis.
There has been reported no image criteria of good response
in treatment of VM. We were concerned about the poten-
tial bias from the questionnaire survey when we used more
generous criteria of good response. Therefore, we used
only marked improvement as a criterion of good response.
In determining image criteria of good response, we arbi-
trary defined marked improvement as 50% reduction of
lesion volume (50% reduction on WBBPS or 30% de-
crease of MRI diameter). In measuring the volume change
of VM lesion, there are several weak points in MRI and
WBBPS. Though “lesion to WBBP ratio” on WBBPS is a
semiquantitative method, it can be affected by increase of
whole body blood pool in patients in their growing age.
With MRI, it is difficult to measure volume of VM lesion
and diameters are not always change equally in all direction.
Despite of these limitations, we think those two are the best
tools currently available to measure volume change of VM
lesion.
There have been previous reports aimed at identifying
predictors of response to sclerotherapy in VM patients.
Puig et al13 proposed a classification scheme of VM based
on the characteristics of venous drainage from the VM
lesion. According to the classification, VMs were classified
into one of four types: type I, isolated malformation with-
out venous drainage; type II, malformation with drainage
Table VI. Multivariate analysisa of variables to predict
“good response” to PES for VM patients
Variables
P
value
Odds
ratio
95% Confidence
interval
Gender, female .022 4.49 1.24-16.28
Age 20 years .352 2.03 0.46-8.97
Location, non-extremity .182 2.28 0.68-7.65
No or delayed visualization of
drainage vein .008 9.22 1.79-47.51
Well-defined margin on MRI .001 13.38 2.84-63.12
Absence of LM or CM
component .376 0.54 0.14-2.12
VM involved to skin and
subcutaneous tissue only .146 0.33 0.07-1.47
VM size 5 cm in diameter .945 1.05 0.28-3.99
Total number of PES 5 sessions .578 1.50 0.35-6.42
Maximal concentration of ethanol
used, 100% .703 0.61 0.46-7.98
Adjuvant treatment with PES .475 1.63 0.43-6.21
PES, Percutaneous ethanol sclerotherapy; VM, venous malformations; LM,
lymphatic malformation; CM, capillary malformation; BW, body weight;
MRI, magnetic resonance imaging.
aBinary logistic regression model.into normal veins; type III, malformation with drainage
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ing to Puig and colleagues, type III and IV lesions are more
difficult to treat with sclerosing agents because of extensive
drainage the normal venous circulation resulting in embolic
complications. Therefore, those VM lesions are deemed
untreatable. Goyal et al11 categorized VM into three cate-
gories based on MRI findings of VM size and marginal
morphology. They reported poor response to percutaneous
sclerotherapy in patients with VM lesion greater than 5 cm
or an ill-defined margin. We also found that no or delayed
visualization of drainage vein on initial direct puncture
venogram and a well-defined margin on MRI were inde-
pendent predictors of good response to PES. However, in
our series, VM size was not a predictor of good response on
multivariate analysis.
To improve the results of sclerotherapy in VM pa-
tients, maintaining long sclerosant dwell time in the
target VM lesion is crucial. Strategies to prolong contact
time between sclerosant and vascular endothelium in-
clude drainage vein compression or the use of foam
sclerosant. Drainage vein compression was achieved manu-
ally under fluoroscopy or utilizing a pneumatic cuff under
fluoroscopy in the extremity.
Recently, the Shanghai group15 reported their 4-year
experience of percutaneous sclerotherapy of venousmalfor-
mations using embolization of the drainage vein with eth-
anol and a subsequent sclerosis therapy with bleomycin A5.
Ethanol infusion into the drainage vein is a method to
prolong dwell time of sclerosant in the target VM lesion.
Berenguer et al10 reported male gender and number of
sclerotherapy sessions as independent predictors of good
outcomes. The findings in our study were different. We
found female gender to be a predictor of “good response”
to PES, and number of PES sessions was not associated
with a “good response”. In our series, 68% of patients with
a good response underwent 2 sessions of PES while 10
patients who underwent 10 sessions of PES did not have
a good response. This suggests that there is a specific group
of patients who respond well to the PES. To minimize
sclerotherapy-related complications, consideration should
be given to whether to repeat PES in patients with a
no-good response in the absence of these predictors of a
good response.
When we compared the demographic, clinical, and
therapeutic variables between female and male patients, we
could not find any significant difference. Further investiga-
tion is needed to address why female patients have a better
response to PES.
In summary, through a cross-sectional, retrospective
analysis, we found that no or slow appearance of drainage
vein on initial direct puncture venography, well-defined
margins on MRI, and female gender were statistically sig-
nificant, independent factors predictive of a good response
to PES in patients with VM. These predictors are clinically
useful in patient selection and can help improve treatment
result and minimize complications. Inferring from our ob-
servation that the slow appearance of drainage vein is
associated with good response to PES, adjuvant techniquesto prolong sclerosant dwell time in the target lesion may
further improve PES results.
The limitations of this study include retrospective de-
sign not covering all VM patients treated with PES and a
lack of standardized assessment tool to compare our results
with other reports.
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questionnaires
This questionnaire asks for your view about outcome
after treatment for venous malformation. For each of the
following three questions, please select the one response
that best describes your answer.
1. How do you have a change in your appearance after
treatment?
a. Markedly worse
b. Moderately worse
c. No change
d. Moderately improved
e. Markedly improved
f. There was no cosmetic problem before treatment2. How do you have a change in your symptom after
treatment?
a. Markedly worse
b. Moderately worse
c. No change
d. Moderately improved
e. Markedly improved
f. There was no symptom before treatment
3. How do you have a change in functional impairment
after treatment?
a. Markedly worse
b. Moderately worse
c. No change
d. Moderately improved
e. Markedly improved
f. There was no functional impairment before treatment
